Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.

Cell death & disease

Volumn 4, Issue , 2013, Pages

  Charette, N ^a   De Saeger, C ^b   Horsmans, Y ^b   Leclercq, I ^b   Starkel P ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIRC5 PROTEIN, HUMAN; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; DRUG DERIVATIVE; FARNESOL; INHIBITOR OF APOPTOSIS PROTEIN; RECOMBINANT PROTEIN; SALICYLIC ACID DERIVATIVE; SALIRASIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL STRAIN HEPG2; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MITOCHONDRION; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; FARNESOL; HEP G2 CELLS; HEPATOCYTES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MITOCHONDRIA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; SALICYLATES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84878978916     PISSN: None     EISSN: 20414889     Source Type: None    
DOI: 10.1038/cddis.2012.200     Document Type: Article

References (0)